• 2235 Citations
  • 26 h-Index
1986 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 19 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Epirubicin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
exemestane Medicine & Life Sciences
Anthracyclines Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1986 2019

  • 2235 Citations
  • 26 h-Index
  • 192 Article
  • 8 Review article
  • 2 Comment/debate

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Gamucci, T., Pizzuti, L., Natoli, C., Mentuccia, L., Sperduti, I., Barba, M., Sergi, D., Iezzi, L., Maugeri-Saccà, M., Vaccaro, A., Magnolfi, E., Gelibter, A., Barchiesi, G., Magri, V., D’Onofrio, L., Cassano, A., Rossi, E., Botticelli, A., Moscetti, L., Omarini, C. & 29 othersFabbri, M. A., Scinto, A. F., Corsi, D., Carbognin, L., Mazzotta, M., Bria, E., Foglietta, J., Samaritani, R., Garufi, C., Mariani, L., Barni, S., Mirabelli, R., Sarmiento, R., Graziano, V., Santini, D., Marchetti, P., Tonini, G., Di Lauro, L., Sanguineti, G., Paoletti, G., Tomao, S., De Maria, R., Veltri, E., Paris, I., Giotta, F., Latorre, A., Giordano, A., Ciliberto, G. & Vici, P., Feb 1 2019, In : Cancer Biology and Therapy. 20, 2, p. 192-200 9 p.

Research output: Contribution to journalArticle

Taxoids
Observational Studies
Retrospective Studies
Breast Neoplasms
Maintenance

Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study

Barni, S., Livraghi, L., Morritti, M., Vici, P., Michelotti, A., Cinieri, S., Fontanella, C., Porcu, L., Del Mastro, L. & Puglisi, F., Jan 1 2019, In : Future Oncology. 15, 1, p. 33-44 12 p.

Research output: Contribution to journalArticle

eribulin
Breast Neoplasms
Safety
Therapeutics
Italy

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Gamucci, T., Pizzuti, L., Natoli, C., Mentuccia, L., Sperduti, I., Barba, M., Sergi, D., Iezzi, L., Maugeri-Saccà, M., Vaccaro, A., Magnolfi, E., Gelibter, A., Barchiesi, G., Magri, V., D'Onofrio, L., Cassano, A., Rossi, E., Botticelli, A., Moscetti, L., Omarini, C. & 29 othersFabbri, M. A., Scinto, A. F., Corsi, D., Carbognin, L., Mazzotta, M., Bria, E., Foglietta, J., Samaritani, R., Garufi, C., Mariani, L., Barni, S., Mirabelli, R., Sarmiento, R., Graziano, V., Santini, D., Marchetti, P., Tonini, G., Di Lauro, L., Sanguineti, G., Paoletti, G., Tomao, S., De Maria, R., Veltri, E., Paris, I., Giotta, F., Latorre, A., Giordano, A., Ciliberto, G. & Vici, P., Nov 7 2018, In : Cancer Biology and Therapy. p. 1-9 9 p.

Research output: Contribution to journalArticle

Taxoids
Observational Studies
Retrospective Studies
Breast Neoplasms
Maintenance
2 Citations (Scopus)

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Pizzuti, L., Sergi, D., Sperduti, I., Lauro, L. D., Mazzotta, M., Botti, C., Izzo, F., Marchetti, L., Tomao, S., Marchetti, P., Natoli, C., Grassadonia, A., Gamucci, T., Mentuccia, L., Magnolfi, E., Vaccaro, A., Cassano, A., Rossi, E., Botticelli, A., Sini, V. & 13 othersSarobba, M. G., Fabbri, M. A., Moscetti, L., Astone, A., Michelotti, A., De Angelis, C., Bertolini, I., Angelini, F., Ciliberto, G., Maugeri-Saccà, M., Giordano, A., Barba, M. & Vici, P., Feb 9 2018, (Accepted/In press) In : Cancer Biology and Therapy. p. 1-7 7 p.

Research output: Contribution to journalArticle

Paclitaxel
Body Mass Index
Breast Neoplasms
Disease-Free Survival
Survival

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer

Pallocca, M., Goeman, F., de Nicola, F., Melucci, E., Sperati, F., Terrenato, I., Pizzuti, L., Casini, B., Gallo, E., Amoreo, C. A., Vici, P., di Lauro, L., Buglioni, S., Diodoro, M. G., Pescarmona, E., Mazzotta, M., Barba, M., Fanciulli, M., de Maria, R., Ciliberto, G. & 1 othersMaugeri-Saccà, M., Sep 4 2018, In : Journal of Translational Medicine. 16, 1, p. 247

Research output: Contribution to journalComment/debate

Chemotherapy
Missense Mutation
Stomach Neoplasms
Mutation
Survival